Nurulamin M Noor, Mrcp

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8821261/publications.pdf

Version: 2024-02-01

33 papers 3,307 citations

15 h-index 642321 23 g-index

34 all docs

34 docs citations

times ranked

34

2753 citing authors

#	Article	IF	CITATIONS
1	ECCO Topical Review on Clinicopathological Spectrum and Differential Diagnosis of Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2022, 16, 343-368.	0.6	17
2	Early Diagnosis, Early Stratification, and Early Intervention to Deliver Precision Medicine in IBD. Inflammatory Bowel Diseases, 2022, 28, 1254-1264.	0.9	27
3	ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment. Journal of Crohn's and Colitis, 2022, 16, 179-189.	0.6	120
4	ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. Journal of Crohn's and Colitis, 2022, 16, 2-17.	0.6	288
5	Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives. The Lancet Gastroenterology and Hepatology, 2022, 7, 171-185.	3.7	57
6	Developing a cadre of clinician trialists in gastroenterology and hepatology. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 211-211.	8.2	0
7	ECCO Position on Harmonisation of Crohn's Disease Mucosal Histopathology. Journal of Crohn's and Colitis, 2022, 16, 876-883.	0.6	21
8	Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019. JAMA Oncology, 2022, 8, 420.	3.4	719
9	Burden of non-communicable diseases among adolescents aged 10–24 years in the EU, 1990–2019: a systematic analysis of the Global Burden of Diseases Study 2019. The Lancet Child and Adolescent Health, 2022, 6, 367-383.	2.7	48
10	Uptake of the multi-arm multi-stage (MAMS) adaptive platform approach: a trial-registry review of late-phase randomised clinical trials. BMJ Open, 2022, 12, e055615.	0.8	8
11	Subgroup analyses in randomised controlled trials frequently categorised continuous subgroup information. Journal of Clinical Epidemiology, 2022, , .	2.4	1
12	Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBDâ€"Disease Outcome and Response to Therapy. Journal of Crohn's and Colitis, 2021, 15, 1431-1442.	0.6	39
13	Moving towards more patient-centred clinical trials in IBD. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 673-674.	8.2	8
14	Global, regional, and national progress towards Sustainable Development Goal 3.2 for neonatal and child health: all-cause and cause-specific mortality findings from the Global Burden of Disease Study 2019. Lancet, The, 2021, 398, 870-905.	6.3	229
15	Perioperative Dietary Therapy in Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2020, 14, 431-444.	0.6	46
16	Personalised medicine in Crohn's disease. The Lancet Gastroenterology and Hepatology, 2020, 5, 80-92.	3.7	55
17	Access to routinely collected health data for clinical trials $\hat{a} \in \text{``review of successful data requests to}$ UK registries. Trials, 2020, 21, 398.	0.7	22
18	Clinical Trials [and Tribulations]: The Immediate Effects of COVID-19 on IBD Clinical Research Activity in the UK. Journal of Crohn's and Colitis, 2020, 14, 1769-1776.	0.6	13

#	Article	IF	CITATIONS
19	Adaptive platform trials using multi-arm, multi-stage protocols: getting fast answers in pandemic settings. F1000Research, 2020, 9, 1109.	0.8	8
20	IDDF2020-ABS-0183â€PROFILE trial: predicting outcomes for Crohn's disease using a molecular biomarker. , 2020, , .		0
21	British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut, 2019, 68, s1-s106.	6.1	1,353
22	Innate and Adaptive Immunology. , 2019, , 313-321.		0
23	Genetic and Genomic Markers for Prognostication. , 2019, , 323-331.		0
24	A blood-based prognostic biomarker in IBD. Gut, 2019, 68, 1386-1395.	6.1	132
25	Validation of the â€~United Registries for Clinical Assessment and Research' [UR-CARE], a European Online Registry for Clinical Care and Research in Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2018, 12, 532-537.	0.6	8
26	PWE-042â€Profile biomarker: effect of steroid treatment on a prognostic gene expression signature. , 2018, , .		0
27	PRedicting Outcomes For Crohn's dIsease using a moLecular biomarkEr (PROFILE): protocol for a multicentre, randomised, biomarker-stratified trial. BMJ Open, 2018, 8, e026767.	0.8	55
28	Investigating Physical Activity in the Etiology of Pancreatic Cancer. Pancreas, 2016, 45, 388-393.	0.5	11
29	Alcoholic ketoacidosis: a case report and review of the literature. Oxford Medical Case Reports, 2016, 2016, 31-33.	0.2	14
30	Selective Decontamination of the Gastrointestinal Tract: A Possible Strategy to Reduce Infection in High-Risk Populations. Gastroenterology & Hepatology (Bartlesville, Okla), 2016, 5, .	0.0	0
31	Investigating the role of physical activity in pancreatic cancer? the age at which this is measured is important in aetiological studies and is independent of body mass index. Pancreatology, 2014, 14, S45.	0.5	0
32	Adaptive platform trials using multi-arm, multi-stage protocols: getting fast answers in pandemic settings. F1000Research, 0, 9, 1109.	0.8	7
33	The Endoscopic Healing Index in Crohn's Disease: A Serum Proteomic Biomarker for Monitoring Disease Activity. Inflammatory Bowel Diseases, 0, , .	0.9	1